Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Leadership & People

Set Alert for Leadership & People

Executives On The Move: Candel Therapeutics, Technoderma Medicines And More

Recent executive changes in the industry include C-suite moves at Bluebird Bio and Jounce Therapeutics. Meanwhile, new directors were appointed at Candel Therapeutics and Technoderma Medicines. 

Executive Changes Leadership

Maureen Kenny, 1963-2022

Kenny, a mainstay of our publications for three decades, has passed away in London.

Regulation BioPharmaceutical

Executives On The Move: Amicus Therapeutics, Perrigo and More

Recent executive moves in the industry include C-suite changes at Amicus Therapeutics and Assembly Biosciences. Meanwhile, new directors were appointed at Torrent Pharmaceuticals and Perrigo, among others.

Executive Changes Leadership

Pharma Braces For Potential Landmark Moment For US Drug Price Controls

US drug pricing legislation that has picked up momentum could stymie R&D investment and curb the revenue tail for some big drugs, industry says, but CEOs also expect they can navigate the challenge. 

Legislation Pricing Debate

Executives On The Move: Herantis Pharma, Cyclerion Therapeutics and More

Recent executive changes in the industry include C-suite changes at Herantis Pharma and MediGene. Meanwhile, new directors were appointed at Cyclerion Therapeutics and Allakos, among others.

Executive Changes Leadership

Pfizer Strengthens Foundation For A Long-Term COVID Commercial Business

Preparing for the eventual transition to an open commercial market for COVID-19 vaccines and treatments, Pfizer restructured its commercial team to incorporate the franchises.

Coronavirus COVID-19 Sales & Earnings

Barron Signs Off With Notes On GSK Culture Change, Tease On RSV Vaccine Results

Hal Barron is leaving just as GSK’s M&A firepower grows following the Haleon spin-out, but sounded a confident note about its potential blockbuster RSV vaccine candidate.

Companies Leadership

Executives On The Move: Alvotech, Small Pharma and More

Recent executive changes in the industry include C-suite changes at Small Pharma and Nuvalent. Meanwhile, new directors were appointed at Alvotech and Versanis Bio, among others.

Executive Changes Leadership

Roche Diagnostics CEO Schinecker Will Succeed Schwan As A New Chapter Unfolds

The Swiss drug maker is preparing for a smooth transition in 2023, appointing 20-year Roche veteran and diagnostic chief Thomas Schinecker as its next chief executive as Severin Schwan becomes chairman.

Leadership Business Strategies

Novartis Finance Chief Rules Out Large M&A

While the correction of the biotech markets downwards increases the chances of bolt-on deals, even with the reduced prices, interesting assets are not so easy to come by, so says Novartis CFO Harry Kirsch.

M & A Business Strategies

Pharma Q2 Preview: Demonstrating Resiliency Against A Turbulent Backdrop

Inflation, rising interest rates, market volatility, violence in Ukraine and a persistent pandemic created a chaotic macroenvironment for doing business. Pharma appears poised to grow, nonetheless.

Business Strategies Sales & Earnings

Executives On The Move: Piramal Pharma, SQZ Biotechnologies and More

Recent executive changes in the industry include C-suite changes at SQZ Biotechnologies and Lineage Cell Therapeutics. Meanwhile, new directors were appointed at Piramal Pharma and Entasis Therapeutics, among others.

Leadership Executive Changes
See All
UsernamePublicRestriction

Register